There have also been preclinical studies using antibodies to target IL-1RAP in CML and AML, but in many cases the mechanism of action is to eliminate IL-1RAP-expressing leukemic cells, rather than direct inhibition of IL-1 signaling (99–101). The gene discussed is IL1A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.